Novel PARG inhibitor FORX-428 has shown best-in-class characteristics in preclinical studiesTrial initially taking place in the U.S., following IND clearanceInitial…
The first patient in Cohort 3, the fifth patient in the trial, has completed the first week of cycle 1…
Reported positive KT-621 (STAT6) Phase 1 healthy volunteer data surpassing Kymera’s target product profile, and further validating its oral, dupilumab-like…
CARVYKTI® (ciltacabtagene autoleucel; cilta-cel) net trade sales of approximately $439 millionCARVYKTI® demonstrated positive long-term outcomes in CARTITUDE-1 study with one-third…
In the ongoing Phase 2/3 study of tovecimig (DLL4 x VEGF-A bispecific antibody) in patients with advanced biliary tract cancer,…
Enrollment in the planned second dose expansion cohort completed ahead of expectationsTopline results expected in Q1 2026 Positive Phase 1b…
• First Patient Dosing Expected in Q1 2026 • Clinical Trial to Prioritize Biomarker-Selected RBM39-Dependent Cancers KING OF PRUSSIA, Pa., Aug.…
STAFFORD, Texas, Aug. 11, 2025 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused…
VANCOUVER, British Columbia, Aug. 11, 2025 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse…
SINGAPORE, Aug. 10, 2025 /PRNewswire/ -- HistoIndex, a pioneering leader in digital pathology solutions for chronic liver disease, has announced…